URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Clive Zent

TitleInterim Professor
InstitutionSchool of Medicine and Dentistry
DepartmentMedicine
AddressUniversity of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester NY 14642
 
 Selected Publications
List All   |   Timeline
  1. Greipp PT, Smoley SA, Viswanatha DS, Frederick LS, Rabe KG, Sharma RG, Slager SL, Van Dyke DL, Shanafelt TD, Tschumper RC, Zent CS. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. Br J Haematol. 2013 Nov; 163(3):326-33.
    View in: PubMed
  2. Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, Laplant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer. 2013 Nov 1; 119(21):3788-96.
    View in: PubMed
  3. Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013 Sep; 162(6):774-82.
    View in: PubMed
  4. Charbonneau B, Wang AH, Maurer MJ, Asmann YW, Zent CS, Link BK, Ansell SM, Weiner GJ, Ozsan N, Feldman AL, Witzig TE, Cunningham JM, Dogan A, Habermann TM, Slager SL, Novak AJ, Cerhan JR. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol Immunother. 2013 Sep; 62(9):1475-84.
    View in: PubMed
  5. Gonsalves WI, Zent CS, Pulido JS, Patnaik MM. Visual loss in early-stage chronic lymphocytic leukemia. J Clin Oncol. 2013 Jun 10; 31(17):e280-2.
    View in: PubMed
  6. Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, Kumar S, Leung N, Dingli D, Dispenzieri A. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2013 May; 88(5):375-8.
    View in: PubMed
  7. Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, Laplant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 2013 May 16; 121(20):4137-41.
    View in: PubMed
  8. Taylor RP, Lindorfer MA, Zent CS. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012 Aug 30; 367(9):876-7; author reply 878.
    View in: PubMed
  9. Zent CS, Wu W, Bowen DA, Hanson CA, Pettinger AM, Shanafelt TD, Kay NE, Leis JF, Call TG. Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leuk Lymphoma. 2013 Mar; 54(3):476-82.
    View in: PubMed
  10. Shanafelt TD, Call TG, Zent CS, Leis JF, Laplant B, Bowen DA, Roos M, Laumann K, Ghosh AK, Lesnick C, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2013 Jan 15; 119(2):363-70.
    View in: PubMed
  11. Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, Ansell SM, Weiner GJ, Wang AH, Witzig TE, Dogan A, Slager SL, Habermann TM, Cerhan JR. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. Am J Hematol. 2012 Sep; 87(9):880-5.
    View in: PubMed
  12. Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, Nowakowski GS, Zent CS. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma. 2012 Nov; 53(11):2218-27.
    View in: PubMed
  13. Zent CS. Improving quality of life in chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Jul; 53(7):1247-8.
    View in: PubMed
  14. Gustafson MP, Abraham RS, Lin Y, Wu W, Gastineau DA, Zent CS, Dietz AB. Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol. 2012 Mar; 156(5):674-6.
    View in: PubMed
  15. Gutierrez A, Arendt BK, Tschumper RC, Kay NE, Zent CS, Jelinek DF. Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression. PLoS One. 2011; 6(10):e26056.
    View in: PubMed
  16. Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG, Shanafelt TD, Bowen DA, Kay NE, Witzig TE, Weiner GJ. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Feb; 53(2):211-7.
    View in: PubMed
  17. Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF, Schwager SM, Thompson CA, Bowen DA, Witzig TE, Slager SL, Call TG. Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer. 2012 Apr 1; 118(7):1827-37.
    View in: PubMed
  18. Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Schwager SM, Leis JF, Jelinek DF, Slager SL, Hanson CA. Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population. Leukemia. 2012 Feb; 26(2):373-6.
    View in: PubMed
  19. Maurer MJ, Cerhan JR, Katzmann JA, Link BK, Allmer C, Zent CS, Call TG, Rabe KG, Hanson CA, Kay NE, Slager SL, Witzig TE, Shanafelt TD. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood. 2011 Sep 8; 118(10):2821-6.
    View in: PubMed
  20. Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE, Nowakowski GS. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin a-4-ß-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 2011 Oct; 155(1):53-64.
    View in: PubMed
  21. Zent CS. Multi-parameter prognostication in chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Oct; 52(10):1823-4.
    View in: PubMed
  22. Chen D, Ketterling RP, Hanson CA, Colgan JP, Zent CS, Viswanatha DS. A case of hairy cell leukemia with CCND1-IGH@ translocation: indolent non-nodal mantle cell lymphoma revisited. Am J Surg Pathol. 2011 Jul; 35(7):1080-4.
    View in: PubMed
  23. Zent CS, Kay NE. Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma. 2011 Aug; 52(8):1425-34.
    View in: PubMed
  24. Zent CS, Polliack A, Tadmor T. FISHing for answers in proliferation centers of chronic lymphocytic leukemia lymph nodes. Leuk Lymphoma. 2011 Jun; 52(6):946-7.
    View in: PubMed
  25. Shanafelt T, Zent C, Byrd J, Erlichman C, Laplant B, Ghosh A, Call T, Villalona-Calero M, Jelinek D, Bowen D, Laumann K, Wu W, Hanson C, Kay N. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Dec; 51(12):2222-9.
    View in: PubMed
  26. Shanafelt TD, Drake MT, Maurer MJ, Allmer C, Rabe KG, Slager SL, Weiner GJ, Call TG, Link BK, Zent CS, Kay NE, Hanson CA, Witzig TE, Cerhan JR. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 2011 Feb 3; 117(5):1492-8.
    View in: PubMed
  27. Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalda MS, Schwager SM, Bowen DA, Slager SL, Hanson CA, Call TG. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010 Oct 15; 116(20):4777-87.
    View in: PubMed
  28. Zent CS. Cell-mediated immunity in chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Oct; 51(10):1775-6.
    View in: PubMed
  29. Shanafelt TD, Rabe KG, Kay NE, Zent CS, Call TG, Slager SL, Bowen DA, Schwager SM, Nowakowski GS. Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Jul; 51(7):1233-40.
    View in: PubMed
  30. Bauer PR, Zent CS, Aubry MC, Ryu JH. Recurrent fevers, cough, and pulmonary opacities in a middle-aged man. Chest. 2010 Jun; 137(6):1465-9.
    View in: PubMed
  31. Zent CS. Time to test CLL p53 function. Blood. 2010 May 27; 115(21):4154-5.
    View in: PubMed
  32. Zent CS, LaPlant BR, Johnston PB, Call TG, Habermann TM, Micallef IN, Witzig TE. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer. 2010 May 1; 116(9):2201-7.
    View in: PubMed
  33. Kay NE, Wu W, Kabat B, LaPlant B, Lin TS, Byrd JC, Jelinek DF, Grever MR, Zent CS, Call TG, Shanafelt TD. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer. 2010 May 1; 116(9):2180-7.
    View in: PubMed
  34. Bowen DA, Call TG, Shanafelt TD, Kay NE, Schwager SM, Reinalda MS, Rabe KG, Slager SL, Zent CS. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma. 2010 Apr; 51(4):620-7.
    View in: PubMed
  35. Jevremovic D, Dronca RS, Morice WG, McPhail ED, Kurtin PJ, Zent CS, Hanson CA. CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res. 2010 Sep; 34(9):1235-8.
    View in: PubMed
  36. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010 Mar; 23(1):47-59.
    View in: PubMed
  37. Zent CS, Van Dyke DL. Detection of recurrent chromosomal defects in chronic lymphocytic leukemia/small lymphocytic lymphoma: innovations and applications. Leuk Lymphoma. 2010 Feb; 51(2):186-7.
    View in: PubMed
  38. Dronca RS, Jevremovic D, Hanson CA, Rabe KG, Shanafelt TD, Morice WG, Call TG, Kay NE, Collins CS, Schwager SM, Slager SL, Zent CS. CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity. Cytometry B Clin Cytom. 2010; 78 Suppl 1:S35-41.
    View in: PubMed
  39. Van Dyke DL, Shanafelt TD, Call TG, Zent CS, Smoley SA, Rabe KG, Schwager SM, Sonbert JC, Slager SL, Kay NE. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol. 2010 Feb; 148(4):544-50.
    View in: PubMed
  40. Pardanani A, Tefferi A, Litzow MR, Zent C, Hogan WJ, McClure RF, Viswanatha D. Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis. Blood. 2009 Oct 15; 114(16):3502-3.
    View in: PubMed
  41. Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK, Secreto CR, Medina KL, Shanafelt TD, Zent CS, Call TG, Kay NE. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol. 2009 Nov; 147(4):471-83.
    View in: PubMed
  42. Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Kay NE, Slager SL. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma. 2009 Aug; 50(8):1261-8.
    View in: PubMed
  43. Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Maddocks K, Jenkins G, Jelinek DF, Morice WG, Boysen J, Schwager S, Bowen D, Slager SL, Hanson CA. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol. 2009 Aug 20; 27(24):3959-63.
    View in: PubMed
  44. Shanafelt TD, Byrd JC, LaPLant B, Zent CS, Call T, Secreto C, Grever MR, Lin TS, Kay NE. Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2009 Sep; 146(6):660-4.
    View in: PubMed
  45. Zent CS, Shanafelt T. Management of autoimmune cytopenia complicating chronic lymphocytic leukemia. Leuk Lymphoma. 2009 Jun; 50(6):863-4.
    View in: PubMed
  46. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol. 2009 Aug 10; 27(23):3808-14.
    View in: PubMed
  47. Nowakowski GS, Hoyer JD, Shanafelt TD, Zent CS, Call TG, Bone ND, Laplant B, Dewald GW, Tschumper RC, Jelinek DF, Witzig TE, Kay NE. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol. 2009 Apr 10; 27(11):1844-9.
    View in: PubMed
  48. Shanafelt TD, Jenkins G, Call TG, Zent CS, Slager S, Bowen DA, Schwager S, Hanson CA, Jelinek DF, Kay NE. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009 Jan 15; 115(2):363-72.
    View in: PubMed
  49. Shanafelt TD, Kay NE, Jenkins G, Call TG, Zent CS, Jelinek DF, Morice WG, Boysen J, Zakko L, Schwager S, Slager SL, Hanson CA. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood. 2009 Apr 30; 113(18):4188-96.
    View in: PubMed
  50. Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood. 2009 Jan 15; 113(3):535-7.
    View in: PubMed
  51. Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA, Secreto CR, Laplant BR, Kabat BF, Kay NE. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008 Oct 15; 113(8):2110-8.
    View in: PubMed
  52. Holtan SG, Porrata LF, Colgan JP, Zent CS, Habermann TM, Markovic SN. mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD). Am J Hematol. 2008 Aug; 83(8):688-9.
    View in: PubMed
  53. Shanafelt TD, Bowen DA, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Tun H, Sloan JA, Call TG. The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. Leuk Res. 2009 Feb; 33(2):263-70.
    View in: PubMed
  54. Zent CS, Secreto CR, LaPlant BR, Bone ND, Call TG, Shanafelt TD, Jelinek DF, Tschumper RC, Kay NE. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res. 2008 Dec; 32(12):1849-56.
    View in: PubMed
  55. Hogan WJ, Zent CS. Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2008 May; 49(5):835-6.
    View in: PubMed
  56. Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Jelinek DF, Kay NE, Shanafelt TD. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol. 2008 May; 141(5):607-14.
    View in: PubMed
  57. Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, Tschumper RC, Bowen DA, Call TG, Shanafelt TD, Kay NE, Slager SL. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol. 2008 May; 141(5):615-21.
    View in: PubMed
  58. Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS, Zent CS, Call TG, Laplant B, Dewald GW, Jelinek DF, Kay NE. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol. 2008 Mar; 140(5):537-46.
    View in: PubMed
  59. Zent CS. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2008 Feb; 49(2):175-6.
    View in: PubMed
  60. Shanafelt TD, Kay NE, Call TG, Zent CS, Jelinek DF, LaPlant B, Morice WG, Hanson CA. MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)? Leuk Res. 2008 Sep; 32(9):1458-61.
    View in: PubMed
  61. Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, Bowen D, Kay N, Shanafelt T. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008 Jan; 49(1):49-56.
    View in: PubMed
  62. Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS, Nowakowski GS, Call TG, Dewald GW, Jelinek DF. Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. J Clin Invest. 2008 Jan; 118(1):306-15.
    View in: PubMed
  63. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007 Dec; 48(12):2412-7.
    View in: PubMed
  64. Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager S, Jelinek DF, Kay NE, Shanafelt TD. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2007 Nov; 139(3):398-404.
    View in: PubMed
  65. Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Sloan JA, Call TG. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007 Oct; 139(2):255-64.
    View in: PubMed
  66. Zent CS, Kay NE. Chronic lymphocytic leukemia: biology and current treatment. Curr Oncol Rep. 2007 Sep; 9(5):345-52.
    View in: PubMed
  67. Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leuk Res. 2007 Dec; 31(12):1737-40.
    View in: PubMed
  68. Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007 Jun 1; 109(11):2291-8.
    View in: PubMed
  69. Ding W, Zent CS. Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/ small lymphocytic lymphoma. Clin Adv Hematol Oncol. 2007 Apr; 5(4):257-61.
    View in: PubMed
  70. Nowakowski GS, Hoyer JD, Shanafelt TD, Geyer SM, LaPlant BR, Call TG, Jelinek DF, Zent CS, Kay NE. Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. Mayo Clin Proc. 2007 Apr; 82(4):449-53.
    View in: PubMed
  71. Rockacy J, Viozzi CF, Zent CS. Mantle cell lymphoma presenting as a slowly enlarging lesion of the floor of mouth in a healthy 72-year-old female: Report of a case. J Oral Maxillofac Surg. 2007 Feb; 65(2):333-7.
    View in: PubMed
  72. Zent CS, Polliack A. Staging chronic lymphocytic leukemia (CLL) for prognosis at diagnosis. Leuk Lymphoma. 2006 Dec; 47(12):2433-4.
    View in: PubMed
  73. Zent CS. Chronic B-cell lymphoproliferative disorders: how many diseases? Leuk Lymphoma. 2006 Oct; 47(10):2006-7.
    View in: PubMed
  74. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006 Oct 1; 24(28):4634-41.
    View in: PubMed
  75. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007 Jan 15; 109(2):405-11.
    View in: PubMed
  76. Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med. 2006 Sep 19; 145(6):435-47.
    View in: PubMed
  77. Lee HB, Lee BH, Pulido JS, Buettner H, Salomão D, Zent CS, Link TP. Intravascular B-cell lymphoma (angiotropic lymphoma) with choroidal involvement. Arch Ophthalmol. 2006 Sep; 124(9):1357-9.
    View in: PubMed
  78. Zent CS, Call TG, Hogan WJ, Shanafelt TD, Kay NE. Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma. 2006 Sep; 47(9):1738-46.
    View in: PubMed
  79. Nora EH, Hamacher KL, Zent CS, Ghosh AK. Indolent systemic mastocytosis as the cause of a long history of unexplained hypotensive episodes. South Med J. 2006 Aug; 99(8):876-9.
    View in: PubMed
  80. Zent CS. Autoimmunity and chronic lymphocytic leukemia. Leuk Lymphoma. 2006 Aug; 47(8):1443-4.
    View in: PubMed
  81. Osborn NK, Ustundag Y, Zent CS, Wiesner RH, Rosen CB, Narayanan Menon KV. Factor XII deficiency acquired by orthotopic liver transplantation: case report and review of the literature. Am J Transplant. 2006 Jul; 6(7):1743-5.
    View in: PubMed
  82. Fink SR, Smoley SA, Stockero KJ, Paternoster SF, Thorland EC, Van Dyke DL, Shanafelt TD, Zent CS, Call TG, Kay NE, Dewald GW. Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2006 Jun; 167(2):177-81.
    View in: PubMed
  83. Stockero KJ, Fink SR, Smoley SA, Paternoster SF, Shanafelt TD, Call TG, Zent CS, Van Dyke DL, Kay NE, Dewald GW. Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2006 Apr 15; 166(2):152-6.
    View in: PubMed
  84. Shanafelt TD, Lee YK, Call TG, Nowakowski GS, Dingli D, Zent CS, Kay NE. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res. 2006 Jun; 30(6):707-12.
    View in: PubMed
  85. Nowakowski GS, Dewald GW, Hoyer JD, Paternoster SF, Stockero KJ, Fink SR, Smoley SA, Remstein ED, Phyliky RL, Call TG, Shanafelt TD, Kay NE, Zent CS. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol. 2005 Jul; 130(1):36-42.
    View in: PubMed
  86. Nowakowski GS, Call TG, Morice WG, Kurtin PJ, Cook RJ, Zent CS. Clinical significance of monoclonal B cells in cerebrospinal fluid. Cytometry B Clin Cytom. 2005 Jan; 63(1):23-7.
    View in: PubMed
  87. Zent CS, Kay NE. Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. Curr Oncol Rep. 2004 Sep; 6(5):348-54.
    View in: PubMed
  88. Zent CS, Chen JB, Kurten RC, Kaushal GP, Lacy HM, Schichman SA. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res. 2004 May; 28(5):495-507.
    View in: PubMed
  89. Kyasa MJ, Hazlett L, Parrish RS, Schichman SA, Zent CS. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma. 2004 Mar; 45(3):507-13.
    View in: PubMed
  90. Zent CS, Kay NE. Update on monoclonal antibody therapy in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2004 Feb; 2(2):107-13.
    View in: PubMed
  91. Kohli M, Zent C, Hutchins LF, Safar M, Dotson P, Mehta P. The academic hematology-oncology firm:a model for postgraduate cancer education. J Cancer Educ. 2004; 19(1):45-9.
    View in: PubMed
  92. Zent CS, Zhan F, Schichman SA, Bumm KH, Lin P, Chen JB, Shaughnessy JD. The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. Leuk Res. 2003 Sep; 27(9):765-74.
    View in: PubMed
  93. Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2003 Sep; 74(1):1-8.
    View in: PubMed
  94. Monson T, Schichman SA, Zent CS. Linezolid-induced pure red blood cell aplasia. Clin Infect Dis. 2002 Aug 1; 35(3):E29-31.
    View in: PubMed
  95. Kohli M, Fink LM, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis. 2002 Jan; 13(1):1-5.
    View in: PubMed
  96. Joseph L, Scott MA, Schichman SA, Zent CS. Localized herpes simplex lymphadenitis mimicking large-cell (Richter's) transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2001 Dec; 68(4):287-91.
    View in: PubMed
  97. Zent CS, Kyasa MJ, Evans R, Schichman SA. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer. 2001 Sep 1; 92(5):1325-30.
    View in: PubMed
  98. Kohli M, Schichman SA, Fink L, Zent CS. Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J. 2000 May; 93(5):469-71.
    View in: PubMed
  99. Govindarajan R, Baxter D, Wilson C, Zent C. Vancomycin-induced thrombocytopenia. Am J Hematol. 1999 Oct; 62(2):122-3.
    View in: PubMed
  100. Zent CS, Ratajczak J, Ratajczak MZ, Anastasi J, Hoffman PC, Gewirtz AM. Relationship between megakaryocyte mass and serum thrombopoietin levels as revealed by a case of cyclic amegakaryocytic thrombocytopenic purpura. Br J Haematol. 1999 May; 105(2):452-8.
    View in: PubMed
  101. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, Munshi N, Bracy D, Barlogie B, Butch AW. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood. 1998 May 1; 91(9):3518-23.
    View in: PubMed
  102. Zent C, Rowley JD, Nucifora G. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies. Leukemia. 1997 Apr; 11 Suppl 3:273-8.
    View in: PubMed
  103. Zent CS, Mathieu C, Claxton DF, Zhang DE, Tenen DG, Rowley JD, Nucifora G. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties. Proc Natl Acad Sci U S A. 1996 Feb 6; 93(3):1044-8.
    View in: PubMed
  104. Zent C, Kim N, Hiebert S, Zhang DE, Tenen DG, Rowley JD, Nucifora G. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties. Curr Top Microbiol Immunol. 1996; 211:243-52.
    View in: PubMed
  105. Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber Lung Dis. 1995 Apr; 76(2):109-13.
    View in: PubMed
  106. Zent C. Drug allergy. S Afr Med J. 1994 May; 84(5):281-6.
    View in: PubMed
  107. Zent CS, Allin R, Folb PI. Prediction of amikacin dose requirements in neutropenic patients with haematological disease. S Afr Med J. 1993 Nov; 83(11):853-4.
    View in: PubMed

Visualizations


Zent's Networks

Concepts
_
Similar People
_
Same Department